anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: An active straight leg raise (SLR) is a weight bearing test which assesses pain upon movement and a patient's ability to load their pelvis, lumbar, and thoracic spine. Since many stable patients undergo computed tomography (CT) scanning solely for spinal tenderness, our hypothesis is that performing active straight leg raising could effectively rule out lumbar and thoracic vertebral fractures.
METHODS: Blunt trauma patients ≥18 years of age with Glasgow Coma Scale 15 presenting in hemodynamically stable condition were screened. Patients remaining in the supine position were asked to perform SLR at 12, 18, and 24 inches above the bed. The patient's ability to raise the leg, baseline pain, and pain at each level were assessed. Patients also underwent standard CT scanning of the chest, abdomen and pelvis. The clinical examination results were then matched post hoc with the official radiology reports.
RESULTS: 99 patients were screened, 65 males and 34 females. Spinal fractures were present in 15/99 patients (16%). Mechanisms of injury included motor vehicle collision 51%, pedestrian struck 25%, fall1 9%, and other 4%. The median pain score of patients with and without significant spinal fractures at 12, 18, 24 inches was 7.5, 7, 6 and 5, 5, 4, respectively. At 24 inches, active SLR had sensitivity of 0.47, a specificity of 0.59, a positive predictive value of 0.17, and an negative predictive value of 0.86.
CONCLUSIONS: Although SLR has been discussed as a useful adjunct to secondary survey and physical exam following blunt trauma, its positive and more importantly negative predictive value are insufficient to rule out spinal column fractures. Liberal indications for CT based upon mechanism and especially pain and tenderness are necessary to identify all thoraco-lumbar spine fractures.
Patients receive ZEN003694 PO QD on days 1-28 or 5 days on and 2 days off, and abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo imaging evaluation, blood sample collection and tumor biopsy throughout the study.
The present invention relates to a method of non-invasive imaging of bacteria. One embodiment involves labeling the bacteria with a radioisotope prior to delivery to the human or animal gut. Another embodiment is to label the bacteriophages, which are then administered to a human or animal, so that they infect (and thus co-localize with) already established bacteria in the human or animal. The phage can then be imaged to show the location of the colonizing bacteria of interest. In another embodiment, the invention more generally relates to labeling bacteria or bacteriophages with radioactive metals or radioisotopes to make the labeled intestinal bacteria and bacteria in vivo visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging. In another embodiment, the invention more generally relates to labeling bacteria or bacteriophages (two or only one) with radioactive metals or radioisotopes to make the enteric bacteria and the bacteria in the body visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging, or by MRI alone or in combination with PET or SPECT.
Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
PURPOSE OF REVIEW: Cardiogenic shock is a clinical syndrome with different causes and a complex pathophysiology. Recent evidence from clinical trials evokes the urgent need for redefining clinical diagnostic criteria to be compliant with the definition of cardiogenic shock and current diagnostic methods.
RECENT FINDINGS: Conflicting results from randomized clinical trials investigating mechanical circulatory support in patients with cardiogenic shock have elicited several extremely important questions. At minimum, it is questionable whether survivors of cardiac arrest should be included in trials focused on cardiogenic shock. Moreover, considering the wide availability of ultrasound and hemodynamic monitors capable of arterial pressure analysis, the current clinical diagnostic criteria based on the presence of hypotension and hypoperfusion have become insufficient. As such, new clinical criteria for the diagnosis of cardiogenic shock should include evidence of low cardiac output and appropriate ventricular filling pressure.
SUMMARY: Clinical diagnostic criteria for cardiogenic shock should be revised to better define cardiac pump failure as a primary cause of hemodynamic compromise.
BACKGROUND: Non-cystic fibrosis bronchiectasis is a chronic respiratory disease characterized by bronchial dilation. However, the significance of elevated eosinophil counts in acute exacerbations of bronchiectasis remains unclear.
METHODS: This retrospective case-control study included 169 hospitalized patients with acute exacerbations of non-cystic fibrosis bronchiectasis. Based on blood eosinophil levels, patients were categorized into eosinophilic and non-eosinophilic bronchiectasis groups. Various clinical variables, including lung function, comorbidities and clinical features were collected for analysis. The study aimed to examine the differences between these groups and their clinical phenotypes.
RESULTS: Eosinophilic bronchiectasis (EB) was present in approximately 22% of all hospitalized patients with bronchiectasis, and it was more prevalent among male smokers (P < 0.01). EB exhibited greater severity of bronchiectasis, including worse airway obstruction, higher scores in the E-FACED (FACED combined with exacerbations) and bronchiectasis severity index (BSI), a high glucocorticoids medication possession ratio, and increased hospitalization cost (P < 0.05 or P < 0.01). Furthermore, we observed a significant positive correlation between blood eosinophil count and both sputum eosinophils (r = 0.49, P < 0.01) and serum total immunoglobulin E levels (r = 0.21, P < 0.05). Additional analysis revealed that patients with EB had a higher frequency of shortness of breath (P < 0.05), were more likely to have comorbid sinusitis (P < 0.01), and exhibited a greater number of lung segments affected by bronchiectasis (P < 0.01).
CONCLUSIONS: These findings suggest that EB presents a distinct pattern of bronchiectasis features, confirming the notion that it is a specific phenotype.
BACKGROUND: Exposure to occupational metallic mixtures has a potential impact on olfactory function. However, research evidence is limited on the potential impact of exposure to metallic mixtures and olfactory dysfunction. Furthermore, the coal dust generated contains multiple various metals during coal mining, and no study yet has focus on the olfactory dysfunction of coal miners.
OBJECTIVES: In this study, we evaluate the association between urinary metallic mixtures and olfactory function in coal miners, while also exploring the potential applicability of plasma olfactory marker protein (OMP) as a biomarker for assessing olfaction.
METHODS: From July to October 2023, coal workers from seven different coal mining enterprises were recruited for the survey when they come for the employee health checkup. Ultimately, 376 participants were met the inclusion criteria and, respectively, determined with the concentrations of urine (16 metals) and plasma (OMP). Meanwhile, applying UPSIT to access their olfactory function. Binary logistic regression and restricted cubic spline (RCS) model were used to estimate the association of individual metals with olfactory function. Bayesian kernel machine regression (BKMR) and Quantile g-computation (QG-C) regression were employed to assess the overall association between metal mixtures and olfactory function and identify the major contributing elements.
RESULTS: In a single-metal model, two metals in urine were found to be significantly associated with olfactory function. RCS analysis further revealed that the association between Iron (Fe) and olfactory function was linear, while Lead (Pb) exhibited a non-linear. The BKMR model demonstrated a significant positive association between metal mixture concentration and olfactory function. Combined QG-C regression analysis suggested that metals Cr, Fe, Se, Sb, and Pb could impact the performance of the olfactory test (UPSIT), with Pb being identified as the most influential contributor. The correlation between plasma OMP protein levels and urinary metal concentrations was weak.
CONCLUSION: Multiple metals are associated with olfactory function in the coal miners. A significant positive association was observed between metal mixture concentrations and olfactory function, with Pb being the most important contributor. In this study, plasma OMP has not been demonstrated to serve as a biomarker for olfactory function.
PROBLEM TO BE SOLVED: To obtain a dental adhesive set capable of surely bonding a dental repairing material to a dentin by a simple operation by combining a specific tooth surface treating agent with a specific adhesive for dentin. SOLUTION: This dental adhesive set is obtained by combining a tooth surface treating agent comprising (A) an acid, (B) an iron salt and/or copper salt and (C) water with an adhesive for dentin comprising (D) methacrylate or acrylate having at least one unsaturated double bond, (E) a polymer not containing an acidic group in the molecule, (F) a polymerization initiator and (G) acetone. Citric acid, oxalic acid, maleic acid or the like is used as the component A and preferably contained in an amount of 1-50wt.% in the tooth surface treating agent. Ferric chloride, cupric chloride, copper acetyl acetone or the like is used as the component B and preferably contained in an amount of 0.0005-50wt.%. Methyl polymethacrylate, ethyl polymethacrylate or the like is preferably used as the component E and preferably contained in an amount of O.5-30wt.% in adhesive for dentin.  Further, the component G is preferably contained in an amount of 10-90wt.%.
Clinical studies of Sodium Oxybate Oral Solution in patients with narcolepsy did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects. In controlled trials in another population, 39 (5%) of 874 patients were 65 years or older. Discontinuations of treatment due to adverse reactions were increased in the elderly compared to younger adults (21% vs. 19%). Frequency of headaches was markedly increased in the elderly (39% vs. 19%). The most common adverse reactions were similar in both age categories. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
1430711 Live bovine adenovirus vaccines RECHERCHE ET INDUSTRIE THERAPEUTIQUES 14 May 1974 [14 May 1973] 21248/74 Heading A5B Temperature-sensitive and substantially non- pathogenic bovine Adenovirus strains are prestrains by bringing a pathogenic bovine Adenovirus strain into contact with a buffered aqueous solution of nitrous acid at from 18‹C to 25‹C and at a pH of from 4.2 to 5 and isolating therefrom, by at least one end dilution passage in a tissue culture known to the art for accepting growth of the Adenovirus and acceptable as a substrate for vaccine production, or temperature-sensitive mutant strain of bovine Adenovirus having a cut-off temperature of from 39 to 40‹C. The temperature-sensitive mutant strain may be isolated by at least one end dilution passage in primary foetal bovine kidney cell culture. The starting bovine Adenovirus strain may be a bovine Adeno 3 virus strain e.g. bovine Adeno 3 virus WBR 1/7 strain. Vaccines for intranasal administration against bovine Adenovirus infections contain as active ingredient a temperature-sensitive bovine Adenovirus strain having a cut-off temperature of from 39 to 40‹C and prepared as above defined. Polyvalent bovine respiratory live virus vaccines administrable by the intranasal route contain as active ingredients the above vaccine and at least one other bovine respiratory live virus vaccine administrable by the intranasal route, e.g. a live infectious bovine rhinotracheitis virus vaccine and a live bovine parainfluenza virus vaccine.
PURPOSE: Grain for enhancing immunity is obtained by nanocoating immunoprotein with an anion type aqueous solution induced from β-glucan and coating grain therewith. The obtained grain is effective in prevention of aging, removal of adult disease and the like. CONSTITUTION: A mixture of 0.001 to 10% by weight of lysozyme, 0.1 to 10% by weight of glucan extracted from a mushroom and 0.001 to 15% by weight of collagen is added to the electrolyzed product of chitosan. The mixture thereof is aged and simultaneously dried in hot blast and cold blast. Thereafter, 0.01 to 15% by weight of immunoprotein is nanocoated with 50 to 90% by weight of the obtained anion type aqueous material induced from β-glucan to produce a composition for enhancing immunity. The composition is sprayed on grain and dried.
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, AND OVERDOSAGE). Gastrointestinal bleeding and ulceration have been reported in patients treated ... 

One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, AND OVERDOSAGE). Gastrointestinal bleeding and ulceration have been reported in patients treated with Potassium Chloride Extended- release Capsules, USP, 8 mEq and 10 mEq (see CONTRAINDICATIONS and WARNINGS). In addition to gastrointestinal bleeding and ulceration, perforation and obstruction have been reported in patients treated with other solid KCl dosage forms, and may occur with Potassium Chloride Extended-release Capsules, USP, 8 mEq and 10 mEq. The most common adverse reactions to the oral potassium salts are nausea, vomiting, flatulence, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time. Skin rash has been reported rarely with potassium preparations. 

To report SUSPECTED ADVERSE EVENTS, contact Adare at 1-877-731-5116 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipient are disclosed. The methods involve administering to a subject antagonists of the receptor which inhibit interaction of the ligand with the receptor, and CD8+ T cell depleting agents. In a preferred embodiment, the molecules on the surface of the T cell which mediate contact-dependent helper effector function are CD154. Preferred CD154 antagonists and CD8+ T cell depleting agents are anti-CD154 and CD8 antibodies. The CD154 antagonists and CD8+ T cell depleting agents are typically administered to a transplant recipient following transplantation of the tissue or organ. The methods of the invention can be used to induce T cell tolerance to transplants such as pancreas, pituitary, liver, kidney, heart, lung, skin, muscle, brain tissue, nerve tissue, stomach, intestines, Adenosine Deaminase-expressing cells, and leptin-expressing cells. A method for treating a skin disorder comprising administering to a subject allogeneic or xenogeneic tissues, organs, or cells expressing donor antigens, CD154 antagonists and CD8+ T cell depleting agents and allogeneic skin graft cells is also disclosed.
Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after PrEP in a retrospective single-center study, including 264 LTx recipients who received PrEP between June 2022 and December 2022, when Omicron BA.5 was the dominant circulating SARS-CoV-2 variant. PrEP was indicated for fully vaccinated patients with poor seroconversion (anti-S <260 BAU/mL). COVID-19 breakthrough infection after PrEP occurred in 11.0% within the first 3 months, increasing to 17.4% within 6 months. Hospitalization rate rose from 27.6% to 52.9% (p = 0.046), while ICU admissions and COVID-19 mortality remained low, respectively occurring in 6.5% and 4.3% of patients with breakthrough infection within 6 months. COVID-19 breakthrough infection and associated hospitalization remained an important problem during the Omicron BA.5 surge in fully vaccinated LTx recipients with deficient seroconversion, despite PrEP with tixagevimab-cilgavimab. However, ICU admissions and COVID-19 mortality were low. Waning of neutralizing effects of PrEP and changing circulating SARS-CoV-2 variants may explain increases in COVID-19 infections and hospitalizations over time after PrEP, highlighting the need for novel, long-term effective PrEP strategies in these high-risk patients.
The invention provides novel compounds and methods of making and using these compounds. In one embodiment, the above compound is of formula (I) wherein R  1  ‑R  7  In the present invention, a definition is given. In yet another embodiment, these compounds are used to modulate P2X  3  Or P2X  2/3  A method of one or both of the receptors. In another embodiment, the compounds are used to treat pain in a patient by administering one or more compounds to the patient. In another embodiment, the compounds are used to treat respiratory dysfunction in a patient by administering one or more compounds to the patient. (I)。
BACKGROUND: Acute lower gastrointestinal bleeding (ALGIB) is a common cause of hospitalization. Recent guidelines recommend the use of prognostic scales for risk stratification. However, it remains unclear whether risk scores are more accurate than some simpler prognostic variables.
OBJECTIVE: To compare the predictive values of haemoglobin alone and the Oakland score for predicting outcomes in ALGIB patients.
DESIGN: Single-centre, retrospective study at a University Hospital. Data were extracted from the hospital's clinical records. The Oakland score was calculated at admission. Study outcomes were defined according to the original article describing the Oakland score: safe discharge (the primary Oakland score outcome), transfusion, rebleeding, readmission, therapeutic intervention and death. Area under the receiver operating characteristics (AUROC) curve and accuracy using haemoglobin and the Oakland score were calculated for each outcome.
RESULTS: Two hundred and fifty-eight patients were included. Eighty-four (32.6%) needed transfusion, 50 (19.4%) presented rebleeding, 31 (12.1%) required therapeutic intervention, 20 (7.8%) were readmitted and six (2.3%) died. There were no differences in the AUROC curve values for haemoglobin versus the Oakland score with regard to safe discharge (0.82 (0.77-0.88) vs 0.80 (0.74-0.86), respectively) or to therapeutic intervention and death. Haemoglobin was significantly better for predicting transfusion and rebleeding, and the Oakland score was significantly better for predicting readmission.
CONCLUSION: In our study, the Oakland score did not perform better than haemoglobin alone for predicting the outcome of patients with ALGIB. The usefulness of risk scores for predicting outcomes in clinical practice remains uncertain.
Patients will be enrolled based on study eligibility criteria. Eligible patients will be scheduled for a Interstim X implant in the operating room. The procedure is completed under anesthesia, either conscious sedation with intubation or breathing assistance. Under fluoroscopic guidance a standard lead will be introduced. Each electrode on the lead will be tested by confirming motor response on at least 3 of 4 leads. Next the implantable pulse generator will be placed in a subcutaneous pocket and secured. Impedance will be tested, 4 standard programs will be set, and then the device will be shut off. The device settings will be adjusted per protocol and the device will be turned on and off during visits 2-7.
OBJECTIVE: Individuals with disease-causing variants in STXBP1 frequently have epilepsy onset in the first year of life with a variety of seizure types, including epileptic spasms. However, the impact of early onset seizures and antiseizure medication (ASM) on the risk of developing epileptic spasms and impact on their trajectory are poorly understood, limiting informed and anticipatory treatment, as well as trial design.
METHODS: We retrospectively reconstructed seizure and medication histories in weekly intervals for individuals with STXBP1 developmental and epileptic encephalopathy (DEE) with epilepsy onset in the first year of life and quantitatively analyzed longitudinal seizure histories and medication response.
RESULTS: We included 61 individuals with early onset seizures, 29 of whom had epileptic spasms. Individuals with neonatal seizures were likely to have continued seizures after the neonatal period (25/26). The risk of developing epileptic spasms was not increased in individuals with neonatal seizures or early infantile seizures (21/41 vs. 8/16, odds ratio [OR] = 1, 95% confidence interval [CI] = .3-3.9, p = 1). We did not find any ASM associated with the development of epileptic spasms following prior seizures. Individuals with prior seizures (n = 16/21, 76%) had a higher risk of developing refractory epileptic spasms (n = 5/8, 63%, OR = 1.9, 95% CI = .2-14.6, p = .6). Individuals with refractory epileptic spasms had a later onset of epileptic spasms (n = 20, median = 20 weeks) compared to individuals with nonrefractory epileptic spasms (n = 8, median = 13 weeks, p = .08).
SIGNIFICANCE: We provide a comprehensive assessment of early onset seizures in STXBP1-DEE and show that the risk of epileptic spasms is not increased following a prior history of early life seizures, nor by certain ASMs. Our study provides baseline information for targeted treatment and prognostication in early life seizures in STXBP1-DEE.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, abdominal surgery, and can be used for thermal mucoclasia of gallbladder. For this purpose during cholecystomy sanitisation of gallbladder is performed. After that into gallbladder cavity introduced is catheter with latex balloon on the end. Then under X-ray control the balloon through syringe is filled with X-ray contrastive solution 90C until the balloon takes contours of gallbladder. After 10 minutes the solution is removed. After that under visual control of endoscope, gallbladder walls are irrigated with 1% methylene blue solution with 5 minute exposure. After that dye is washed off and degree of mucosa dying is estimated. In case if all parts of mucosa are dyed into blue colour efficiency of mucoclasia is proved. In case if undyed sections are present mucoplasia procedure is repeated. ^ EFFECT: method allows simultaneously without preliminary obliteration of bladder duct under visual control to carry out demucosation of gallbladder cavity aimed at its further obliteration and simultaneously estimate its efficiency, avoid complications, considerably reduce patient's stay in hospital. ^ 1 ex
The subjects will come for a screening visit at week 0 (baseline), then at week 6, week 12, and week 16 for Chinese medicine practitioner (CMP) investigators assessments. Eczema Area and Severity Index (EASI), Children's Dermatology Life Quality Index (CDLQI), Patient-Oriented Eczema Measure (POEM), and Chinese Medicine body constitution types will be assessed and filled up at different timepoints. They will receive oral herbal mQYD or placebo granules for 12 weeks and then be followed up 4 weeks after the treatment. Registered CMPs will provide consultation under Chinese medicine theory. Study medication compliance and adverse events will also be assessed at each visit. Besides, they need to record the food taken in a diary before the day for taking faecal specimen for gut microbiome analysis.